Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
2.
J Neurosci Methods ; 61(1-2): 113-8, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8618408

RESUMO

Methyllycaconitine (MLA) is the most potent and selective antagonist of the alpha-bungarotoxin sensitive neuronal nicotinic acetylcholine receptor (nAChR). In the present study, an accurate and reproducible technique for the extraction and analysis of MLA from rat plasma and brain is described. This study further sought to determine whether pharmacologically relevant concentrations of MLA could be achieved in brain following peripheral administration. The detection limits for MLA were 0.5 ng/ml for plasma samples and 1.0 ng/g for brain samples. The pharmacokinetic properties of MLA in rat are characterized by a short elimination half-life (19 min) following intravenous (i.v.) administration and poor bioavailability following oral (p.o.) administration. Remarkably, the elimination half-life is significantly longer following p.o. administration (408 min). To assess the extent to which MLA can penetrate into brain, brain and plasma levels of MLA were determined at different time points following intraperitoneal (i.p.) administration of a dose of MLA that produced no observable side effects. Maximal plasma and brain levels were 694 +/- 106 ng/ml and 32 +/- 3 ng/g, respectively. These concentrations are within a range previously reported to selectively block alpha 7 nAChR mediated responses in vitro. Peripherally administered MLA may therefore be a useful tool to further probe the central nervous system functions of the alpha 7 nAChR subunit in vivo.


Assuntos
Aconitina/análogos & derivados , Encéfalo/metabolismo , Cromatografia Líquida de Alta Pressão/métodos , Inseticidas/metabolismo , Antagonistas Nicotínicos/metabolismo , Aconitina/metabolismo , Animais , Masculino , Ratos , Ratos Sprague-Dawley
3.
Bioorg Med Chem Lett ; 9(20): 2963-8, 1999 Oct 18.
Artigo em Inglês | MEDLINE | ID: mdl-10571156

RESUMO

SQBAzide, a biotinylated, azido derivative of the TXA2 receptor antagonist, SQ31,491, was synthesized and characterized. The compound specifically inhibited human platelet aggregation mediated by TXA2 receptor activation and irreversibly labeled platelet TXA2 receptors upon exposure to ultraviolet light. This probe should prove to be of significant value for the study of the receptor-ligand binding domain.


Assuntos
Azidas/síntese química , Biotina/análogos & derivados , Plaquetas/metabolismo , Marcadores de Fotoafinidade/síntese química , Receptores de Tromboxanos/metabolismo , Azidas/metabolismo , Biotina/síntese química , Biotina/metabolismo , Humanos , Marcadores de Fotoafinidade/metabolismo , Inibidores da Agregação Plaquetária/síntese química , Inibidores da Agregação Plaquetária/metabolismo , Receptores de Tromboxanos/agonistas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA